Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy

Open access
Khanna, Dinesh, Chong, Kelvin K.L., Afifiyan, Nikoo F., Hwang, Catherine J., Lee, Diana K., Garneau, Helene Chokron, Goldberg, Robert A., Darwin, Christine H., Smith, Terry J., Douglas, Raymond S. · 2010 · Ophthalmology

Abstract

Purpose To study the effectiveness of anti-CD20 (Rituximab, RTX, Rituxan®, Genentech Inc. USA) therapy in patients with severe, corticosteroid (CS)-resistant thyroid-associated ophthalmopathy (TAO). Design Retrospective interventional case series Participants Six consecutive subjects with severe, progressive TAO unresponsive to CS. Methods Electronic medical record review of consecutive patients receiving RTX during the previous 18 months. Responses to therapy were graded using standard clinical assessment and flow-cytometric analysis of peripheral lymphocytes. Main outcome measures Clinical activity score (CAS), proptosis, strabismus, treatment side-effects, and quantification of regulatory T cells. Results Six patients were studied. Systemic CS failed to alter clinical activity in all patients (CAS= 5.3 + 1.0 (mean + standard deviation) before vs 5.5 + 0.8 during therapy for 7.5+ 6.4 months, p=1.0). However following RTX treatment, CAS improved from 5.5 + 0.8 to 1.3 + 0.5 at 2 months post treatment (p<0.03) and remained quiescent in all patients (CAS=0.7 + 0.8; p≤0.0001) at 6.2 + 4.5 month follow-up. Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). None of the six patients experienced disease relapse following RTX infusion and proptosis remained stable (Hertel measurement = 24 + 3.7mm before and 23.6 + 3.7mm after therapy, p=0.17). The abundance of T regulatory cells, assessed in one patient, increased within one week of RTX and remained elevated at 18 month follow-up. Conclusions In progressive, CS-resistant TAO, rapid and sustained resolution of orbital inflammation and DON followed treatment with RTX.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2009.05.029

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 172

Metadata

Authors
Khanna, D., Chong, K. K. L., Afifiyan, N. F., Hwang, C. J., Lee, D. K., Garneau, H. C., Goldberg, R. A., Darwin, C. H., Smith, T. J., & Douglas, R. S.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2010-01
Volume
117
Issue
1
Pages
133-139.e2
ISSN
0161-6420 (ISSN-L)
OpenAlex
W2117679518
Cited by
172
References
2
FWCI
9.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy. https://app.cochat.ai/papers/10.1016/j.ophtha.2009.05.029
The paper
Khanna, D., Chong, K. K. L., Afifiyan, N. F., Hwang, C. J., Lee, D. K., Garneau, H. C., Goldberg, R. A., Darwin, C. H., Smith, T. J., & Douglas, R. S. (2010). Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy. Ophthalmology. https://doi.org/10.1016/j.ophtha.2009.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.